William Gassen Buys Shares of HealthEquity, Inc.
Insider William Gassen acquired 2,877 shares of HealthEquity, Inc. on June 25, 2026.
Key Points
- William Gassen purchased 2,877 shares of HealthEquity, Inc. on June 25, 2026, with shares trading at $88.58.
- HealthEquity, Inc. has a market cap of $7.39 billion and a P/E ratio of 33.1, with shares ranging from $72.76 to $106.60 over the past year.
- Analysts from Citizens and RBC Capital maintained a 'buy' rating, with price targets of $111 and $108, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, William Gassen, an insider at HealthEquity, Inc. (NasdaqGS: HQY), purchased 2,877 shares of the company. The shares were acquired without a specified price, and the transaction was not part of a pre-planned trading program. Shares of HealthEquity traded at $88.58 on Tuesday.
Insider Buying and Selling at HealthEquity, Inc.
William Gassen wasn't the only insider buying shares on June 25, 2026. Other insiders, including Gayle Furgurson Wellborn, Stuart Parker, Evelyn Dilsaver, Debra Charlotte McCowan, and Adrian Dillon, also each acquired 2,877 shares. These purchases were made without a specified price and were similarly not pre-planned.
HealthEquity, Inc. Stock Down 8.1%
Shares of HealthEquity, Inc. traded near $88.58 on Tuesday. The company boasts a market capitalization of approximately $7.39 billion, with a P/E ratio of 33.1 and a forward P/E of 16.1. The stock has seen a 52-week low of $72.76 and a high of $106.60. Its 50-day moving average is $85.12, while the 200-day moving average stands at $88.09. HealthEquity maintains a strong current ratio of 3.44 and a quick ratio of 2.85, with a debt-to-equity ratio of 48.09.
$HQY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been positive on HealthEquity, Inc., with Citizens maintaining a 'buy' rating and setting a price target of $111 on June 1, 2026. RBC Capital also maintained its 'buy' rating with a target of $108 on May 29, 2026. Barrington Research echoed this sentiment with a 'buy' rating and a $110 target on May 22, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price of $115.56 based on 16 opinions.
About HealthEquity, Inc.
HealthEquity, Inc. is a healthcare company based in Draper, Utah, providing technology-enabled services to consumers and employers in the U.S. It offers health savings accounts, flexible spending accounts, and health reimbursement arrangements, among other services. The company also assists with commuter benefits and COBRA continuation services. Led by CEO Scott R. Cutler, HealthEquity employs approximately 2,814 people.
Bottom Line
William Gassen's purchase of HealthEquity shares underscores insider confidence in the company's prospects. Investors often track insider buying as a potential indicator of a company's future performance. However, it's important to remember that such purchases don't guarantee future stock movement. HealthEquity, Inc. continues to attract positive analyst attention, with a consensus 'buy' rating and several recent price target affirmations.
Get HealthEquity, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HQY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.